Lung Cancer: Overview

Chapter

Abstract

Lung cancer is the leading cause of cancer-related death in the world and 90% of all cases are caused by tobacco smoking. Lung cancer is divided into two major histologic subtypes, non-small cell (NSCLC) and small cell (SCLC), with distinct biological behavior, genetic alterations, and therapy. Thus far, screening for lung cancer has not been proven effective since no modality has been shown to decrease mortality. Most patients with both SCLC and NSCLC present with symptoms of either locally advanced or metastatic disease, with only about 25% of patients with NSCLC having early-stage, resectable disease. For patients with stage I or II NSCLC, surgical resection is the treatment of choice and results in long-term survival in 60–80% or 40–50% of patients, respectively. For patients with stage III, locally advanced NSCLC or limited-stage SCLC, aggressive chemotherapy plus radiotherapy can offer a cure in 20–25% of patients. Stage IV, or metastatic, NSCLC and extensive-stage SCLC are incurable diseases in which chemotherapy can prolong survival and palliate symptoms. Recent advances in our understanding of the molecular biology of lung cancer have led to novel therapeutic strategies targeting relevant pathways that regulate the proliferation and/or progression of lung cancer. Several of these molecularly targeted therapies have now demonstrated significant clinical benefits in subsets of patients with lung cancer.

Keywords

Depression Arsenic Income Aspirin Polycyclic Aromatic Hydrocarbon 

References

  1. 1.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2009; 59:225–249.PubMedGoogle Scholar
  2. 2.
    Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 2008; 3:819–831.PubMedGoogle Scholar
  3. 3.
    Weiss W. Cigarette smoking and lung cancer trends. A light at the end of the tunnel? Chest 1997; 111:1414–1416.PubMedGoogle Scholar
  4. 4.
    Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930–1998. Cancer 2003; 97:3133–3275.PubMedGoogle Scholar
  5. 5.
    Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases. J Am Med Assoc 1950; 143:329–336.PubMedGoogle Scholar
  6. 6.
    Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. Br Med J 1950; 2:739–748.Google Scholar
  7. 7.
    Giovino GA. The tobacco epidemic in the United States. Am J Prev Med 2007; 33:S318–S326.Google Scholar
  8. 8.
    Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska natives. Cancer 2007; 110:2119–2152.Google Scholar
  9. 9.
    Abidoye O, Ferguson MK, Salgia R. Lung carcinoma in African Americans. Nat Clin Pract Oncol 2007; 4:118–129.PubMedGoogle Scholar
  10. 10.
    Gadgeel SM, Kalemkerian GP. Racial differences in lung cancer. Cancer Metastasis Rev 2003; 22:39–46.PubMedGoogle Scholar
  11. 11.
    Albano JD, Ward E, Jemal A, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst 2007; 99:1384–1394.PubMedGoogle Scholar
  12. 12.
    Devesa SS, Diamond EL. Socioeconomic and racial differences in lung cancer incidence. Am J Epidemiol 1983; 118:818–831.PubMedGoogle Scholar
  13. 13.
    Krieger N, Quesenberry C, Jr., Peng T, et al. Social class, race/ethnicity, and incidence of breast, cervix, colon, lung, and prostate cancer among Asian, Black, Hispanic, and White residents of the San Francisco Bay Area, 1988–92 (United States). Cancer Causes Control 1999; 10:525–537.PubMedGoogle Scholar
  14. 14.
    Baquet CR, Horm JW, Gibbs T, et al. Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst 1991; 83:551–557.PubMedGoogle Scholar
  15. 15.
    Gridelli C, Langer C, Maione P, et al. Lung cancer in the elderly. J Clin Oncol 2007; 25:1898–1907.PubMedGoogle Scholar
  16. 16.
    State-specific prevalence of cigarette smoking and quitting among adults–United States, 2004. MMWR Morb Mortal Wkly Rep 2005; 54:1124–1127.Google Scholar
  17. 17.
    Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:29S–55S.PubMedGoogle Scholar
  18. 18.
    Patel JD. Lung cancer in women. J Clin Oncol 2005; 23:3212–3218.PubMedGoogle Scholar
  19. 19.
    Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. Int J Epidemiol 2007; 36:1048–1059.PubMedGoogle Scholar
  20. 20.
    Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol 2007; 25:472–478.PubMedGoogle Scholar
  21. 21.
    Gorlova OY, Zhang Y, Schabath MB, et al. Never smokers and lung cancer risk: a case-control study of epidemiological factors. Int J Cancer 2006; 118:1798–1804.PubMedGoogle Scholar
  22. 22.
    Neuberger JS, Field RW. Occupation and lung cancer in nonsmokers. Rev Environ Health 2003; 18:251–267.PubMedGoogle Scholar
  23. 23.
    Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol 1999; 149:13–20.PubMedGoogle Scholar
  24. 24.
    Wu AH, Fontham ET, Reynolds P, et al. Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1996; 143:535–542.PubMedGoogle Scholar
  25. 25.
    Nordquist LT, Simon GR, Cantor A, et al. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004; 126:347–351.PubMedGoogle Scholar
  26. 26.
    Brownson RC, Loy TS, Ingram E, et al. Lung cancer in nonsmoking women. Histology and survival patterns. Cancer 1995; 75:29–33.PubMedGoogle Scholar
  27. 27.
    Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123–132.PubMedGoogle Scholar
  28. 28.
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129–2139.PubMedGoogle Scholar
  29. 29.
    Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497–1500.PubMedGoogle Scholar
  30. 30.
    Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006; 12:1647–1653.PubMedGoogle Scholar
  31. 31.
    Le CF, Mukeria A, Hunt JD, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 2005; 65:5076–5083.Google Scholar
  32. 32.
    Doll R. Mortality from lung cancer in asbestos workers. Br J Ind Med 1955; 12:81–86.PubMedGoogle Scholar
  33. 33.
    Lubin JH, Boice JD, Jr., Edling C, et al. Lung cancer in radon-exposed miners and estimation of risk from indoor exposure. J Natl Cancer Inst 1995; 87:817–827.PubMedGoogle Scholar
  34. 34.
    Tockman MS, Anthonisen NR, Wright EC, et al. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987; 106:512–518.PubMedGoogle Scholar
  35. 35.
    de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 2007; 132:1932–1938.PubMedGoogle Scholar
  36. 36.
    Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med 2005; 11:431–437.PubMedGoogle Scholar
  37. 37.
    Skuladottir H, Tjoenneland A, Overvad K, et al. Does insufficient adjustment for smoking explain the preventive effects of fruit and vegetables on lung cancer? Lung Cancer 2004; 45:1–10.PubMedGoogle Scholar
  38. 38.
    Holick CN, Michaud DS, Stolzenberg-Solomon R, et al. Dietary carotenoids, serum beta-carotene, and retinol and risk of lung cancer in the alpha-tocopherol, beta-carotene cohort study. Am J Epidemiol 2002; 156:536–547.PubMedGoogle Scholar
  39. 39.
    The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330:1029–1035.Google Scholar
  40. 40.
    Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150–1155.PubMedGoogle Scholar
  41. 41.
    Paolini M, Cantelli-Forti G, Perocco P, et al. Co-carcinogenic effect of beta-carotene. Nature 1999; 398:760–761.PubMedGoogle Scholar
  42. 42.
    Paolini M, Antelli A, Pozzetti L, et al. Induction of cytochrome P450 enzymes and over-generation of oxygen radicals in beta-carotene supplemented rats. Carcinogenesis 2001; 22:1483–1495.PubMedGoogle Scholar
  43. 43.
    Arora A, Willhite CA, Liebler DC. Interactions of beta-carotene and cigarette smoke in human bronchial epithelial cells. Carcinogenesis 2001; 22:1173–1178.PubMedGoogle Scholar
  44. 44.
    Tokuhata GK, Lilienfeld AM. Familial aggregation of lung cancer in humans. J Natl Cancer Inst 1963; 30:289–312.PubMedGoogle Scholar
  45. 45.
    Schwartz AG, Yang P, Swanson GM. Familial risk of lung cancer among nonsmokers and their relatives. Am J Epidemiol 1996; 144:554–562.PubMedGoogle Scholar
  46. 46.
    Cote ML, Kardia SL, Wenzlaff AS, et al. Risk of lung cancer among white and black relatives of individuals with early-onset lung cancer. JAMA 2005; 293:3036–3042.PubMedGoogle Scholar
  47. 47.
    Etzel CJ, Amos CI, Spitz MR. Risk for smoking-related cancer among relatives of lung cancer patients. Cancer Res 2003; 63:8531–8535.PubMedGoogle Scholar
  48. 48.
    Sellers TA, Bailey-Wilson JE, Elston RC, et al. Evidence for mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst 1990; 82:1272–1279.PubMedGoogle Scholar
  49. 49.
    Braun MM, Caporaso NE, Page WF, et al. Genetic component of lung cancer: cohort study of twins. Lancet 1994; 344:440–443.PubMedGoogle Scholar
  50. 50.
    Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250:1233–1238.PubMedGoogle Scholar
  51. 51.
    Vineis P, Veglia F, Benhamou S, et al. CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer 2003; 104:650–657.PubMedGoogle Scholar
  52. 52.
    Vineis P, Veglia F, Anttila S, et al. CYP1A1, GSTM1 and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene–gene interactions. Biomarkers 2004; 9:298–305.PubMedGoogle Scholar
  53. 53.
    Yu D, Zhang X, Liu J, et al. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res 2008; 14:2878–2886.PubMedGoogle Scholar
  54. 54.
    Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Seminars in Roentgenology 2005; 40:90–97.PubMedGoogle Scholar
  55. 55.
    Wingo PA, Ries LA, Giovino GA, et al. Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999; 91:675–690.Google Scholar
  56. 56.
    Devesa SS, Shaw GL, Blot WJ. Changing patterns of lung cancer incidence by histological type. Cancer Epidemiol Biomarkers Prev 1991; 1:29–34.PubMedGoogle Scholar
  57. 57.
    Brooks DR, Austin JH, Heelan RT, et al. Influence of type of cigarette on peripheral versus central lung cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:576–581.PubMedGoogle Scholar
  58. 58.
    Schuller HM. Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2002; 2:455–463.PubMedGoogle Scholar
  59. 59.
    Pan H, Califano J, Ponte JF, et al. Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. Cancer Res 2005; 65:1664–1669.PubMedGoogle Scholar
  60. 60.
    Sundaresan V, Heppell-Parton A, Coleman N, et al. Somatic genetic changes in lung cancer and precancerous lesions. Ann Oncol 1995; 6:27–31.PubMedGoogle Scholar
  61. 61.
    Franklin WA, Gazdar AF, Haney J, et al. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest 1997; 100:2133–2137.PubMedGoogle Scholar
  62. 62.
    Panani AD, Roussos C. Cytogenetic and molecular aspects of lung cancer. Cancer Lett 2006; 239:1–9.PubMedGoogle Scholar
  63. 63.
    Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 2001; 61:1309–1313.PubMedGoogle Scholar
  64. 64.
    Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers – a different disease. Nat Rev Cancer 2007; 7:778–790.PubMedGoogle Scholar
  65. 65.
    Gradowski JF, Mantha GS, Hunt JL, et al. Molecular alterations in atypical adenomatous hyperplasia occurring in benign and cancer-bearing lungs. Diagn Mol Pathol 2007; 16:87–90.PubMedGoogle Scholar
  66. 66.
    Wistuba II, Behrens C, Milchgrub S, et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999; 18:643–650.PubMedGoogle Scholar
  67. 67.
    Davies SJ, Gosney JR, Hansell DM, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax 2007; 62:248–252.PubMedGoogle Scholar
  68. 68.
    The Surgeon General's 1990 Report on The Health Benefits of Smoking Cessation. Executive Summary. MMWR Recomm Rep 1990; 39:i-12.Google Scholar
  69. 69.
    Kenfield SA, Stampfer MJ, Rosner BA, et al. Smoking and smoking cessation in relation to mortality in women. JAMA 2008; 299:2037–2047.PubMedGoogle Scholar
  70. 70.
    The HOPE and HOPE-TOO Trial Investigators. Effects of long-term Vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA 2005; 293:1338–1347.Google Scholar
  71. 71.
    Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001; 93:605–618.PubMedGoogle Scholar
  72. 72.
    Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004; 431:405–406.PubMedGoogle Scholar
  73. 73.
    Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296:313–316.Google Scholar
  74. 74.
    Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294:47–55.PubMedGoogle Scholar
  75. 75.
    Kim ES, Hong WK, Lee JJ, et al. A randomized double-blind study of the biological effects of celecoxib as a chemopreventive agent in current and former smokers. J Clin Oncol (Meeting Abstracts) 2008; 26:1501.Google Scholar
  76. 76.
    Clark LC, Combs GF, Jr., Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276:1957–1963.PubMedGoogle Scholar
  77. 77.
    Frost JK, Ball WC, Jr., Levin ML, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis 1984; 130:549–554.PubMedGoogle Scholar
  78. 78.
    Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000; 92:1308–1316.PubMedGoogle Scholar
  79. 79.
    Melamed MR, Flehinger BJ, Zaman MB, et al. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 1984; 86:44–53.PubMedGoogle Scholar
  80. 80.
    Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355:1763–1771.PubMedGoogle Scholar
  81. 81.
    Carbone, PP, Frost, JK, Feinstein, AR, et al. Lung cancer: perspectives and prospects. Ann Intern Med 1970; 73:1003–1024.Google Scholar
  82. 82.
    Chute CG, Greenberg ER, Baron J, et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 1985; 56:2107–2111.PubMedGoogle Scholar
  83. 83.
    Spiro SG, Gould MK, Colice GL. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132:149S–160S.PubMedGoogle Scholar
  84. 84.
    Muers MF, Round CE. Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax 1993; 48:339–343.PubMedGoogle Scholar
  85. 85.
    Fuller RW, Jackson DM. Physiology and treatment of cough. Thorax 1990; 45:425–430.PubMedGoogle Scholar
  86. 86.
    Gottlieb LS, Hillberg R. Endobronchial tamponade therapy for intractable hemoptysis. Chest 1975; 67:482–483.PubMedGoogle Scholar
  87. 87.
    Hsu AA. Thoracic embolotherapy for life-threatening haemoptysis: a pulmonologist's perspective. Respirology 2005; 10:138–143.PubMedGoogle Scholar
  88. 88.
    Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57:939–944.PubMedGoogle Scholar
  89. 89.
    Bruera E, de SN, Velasco-Leiva A, et al. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993; 342:13–14.PubMedGoogle Scholar
  90. 90.
    Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine (Baltimore) 2006; 85:37–42.PubMedGoogle Scholar
  91. 91.
    Rusch VW. Management of Pancoast tumours. Lancet Oncol 2006; 7:997–1005.PubMedGoogle Scholar
  92. 92.
    Kelly K, Bunn PA, Jr. Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer 1998; 20:85–91.PubMedGoogle Scholar
  93. 93.
    Hirsch FR, Paulson OB, Hansen HH, Vraa-Jensen J. Intracranial metastases in small cell carcinoma of the lung: correlation of clinical and autopsy findings. Cancer 1982; 50:2433–2437.PubMedGoogle Scholar
  94. 94.
    Carolan H, Sun AY, Bezjak A, et al. Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? Lung Cancer 2005; 49:109–115.PubMedGoogle Scholar
  95. 95.
    Chamberlain MC. Neoplastic meningitis. Oncologist 2008; 13:967–977.PubMedGoogle Scholar
  96. 96.
    Davis PC, Hudgins PA, Peterman SB, Hoffman JC, Jr. Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. AJNR Am J Neuroradiol 1991; 12:293–300.PubMedGoogle Scholar
  97. 97.
    Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008; 26:1142–1147.PubMedGoogle Scholar
  98. 98.
    Carlsen K, Jensen AB, Jacobsen E, et al. Psychosocial aspects of lung cancer. Lung Cancer 2005; 47:293–300.PubMedGoogle Scholar
  99. 99.
    Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710–1717.PubMedGoogle Scholar
  100. 100.
    Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2:706–714.PubMedGoogle Scholar
  101. 101.
    Argiris A, Murren JR. Staging and clinical prognostic factors for small-cell lung cancer. Cancer J 2001; 7:437–447.PubMedGoogle Scholar
  102. 102.
    Toloza EM, Harpole L, Detterbeck F, et al. Invasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123:157S–166S.PubMedGoogle Scholar
  103. 103.
    Mandrekar SJ, Schild SE, Hillman SL, et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 2006; 107:781–792.PubMedGoogle Scholar
  104. 104.
    Ou SH, Zell JA, Ziogas A, et al. Prognostic factors for survival of stage I non-small cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer 2007; 110:1532–1541.PubMedGoogle Scholar
  105. 105.
    Scott WJ, Howington J, Feigenberg S, et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:234S–242S.PubMedGoogle Scholar
  106. 106.
    Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26:3552–3559.PubMedGoogle Scholar
  107. 107.
    Robinson LA, Ruckdeschel JC, Wagner H, Jr., et al. Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest 2007; 132:243S–265.PubMedGoogle Scholar
  108. 108.
    Jett JR, Schild SE, Keith RL, et al. Treatment of Non-small Cell Lung Cancer, Stage IIIB: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest 2007; 132:266S–276.PubMedGoogle Scholar
  109. 109.
    Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol (Meeting Abstracts) 2005; 23:7014.Google Scholar
  110. 110.
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92–98.PubMedGoogle Scholar
  111. 111.
    Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542–2550.PubMedGoogle Scholar
  112. 112.
    Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589–1597.PubMedGoogle Scholar
  113. 113.
    Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007; 132:324S–3339.PubMedGoogle Scholar
  114. 114.
    Turrisi AT, III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265–271.PubMedGoogle Scholar
  115. 115.
    Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341:476–484.PubMedGoogle Scholar
  116. 116.
    Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357:664–672.PubMedGoogle Scholar
  117. 117.
    Fu JB, Kau Y, Severson RK, et al. Lung cancer in women: analysis of the national surviellance, epidemiology, and end results database. Chest 2005; 127:768–777.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Wayne State University/Karmanos Cancer InstituteDetroitUSA
  2. 2.Division of Hematology/Oncology, Department of Internal Medicine, University of MichiganAnn ArborUSA

Personalised recommendations